Etranacogene dezaparvovec
As of the edition of 20 October 2026, Etranacogene dezaparvovec is a gene: marketed, first approved in 2022 (US); US protection ends in 2034.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Gene
- Brand name
- Hemgenix
- First approved
- 22 November 2022 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- CSL Behring; 2 holders in all
US protection
US protection ends in 2034.
The reference-product exclusivity ends in 2034. The application that gives this date is held by CSL Behring.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| CSL Behring | Originator and Applicant | 2022 to now |